Atea Pharmaceuticals Inc (AVIR)
🔔 Watch stock
Appears in These Scanners
This stock currently matches 7 of our scanner strategies — each hit links to the scanner.
Only genuine hits from verified scanners count; pure ranking metrics (P/E, P/S, and similar, which just sort the whole universe) don't count as a hit. View all scanners
Basics
Performance
Valuation
Profitability
Balance Sheet & Safety
Growth
Quality & Screener
AI Rating
Uses AIAtea Pharmaceuticals ist ein Antiviren-Biotech (HCV-Kandidat) ohne jede KI-Umsatzquelle; im 10-K FY2025 und im 10-Q Q1/2026 erklärt Atea aber ausdrücklich und wiederholt, den eigenen KI-Einsatz auszuweiten („We are increasing our use of AI tools and technology throughout our business“) — flankiert von Risiko-Passagen zu KI-Regulierung und einem möglichen Wettbewerbsnachteil, falls Konkurrenten KI in der Wirkstoffsuche besser nutzen. Das ist belegter operativer KI-Einsatz, kein konkretes Bedrohungs-Szenario fürs Geschäftsmodell; die drei älteren 10-Qs und das 10-K FY2024 sind komplett ohne KI-Erwähnung.
View the full file — quotes, sources, reviewed filings
„Our business may be affected by the evolving regulatory framework relating to the use of AI. We are increasing our use of AI tools and technology throughout our business. The regulatory framework for AI is rapidly evolving as many federal, state, and foreign government bodies and agencies have introduced or are currently considering additional laws and regulations."
Unser Geschäft könnte durch den sich entwickelnden Rechtsrahmen für den Einsatz von KI beeinträchtigt werden. Wir weiten den Einsatz von KI-Werkzeugen und -Technologien in unserem gesamten Geschäftsbetrieb aus. Der Rechtsrahmen für KI entwickelt sich rasant, da viele Regierungsstellen und Behörden auf Bundes-, Bundesstaats- und ausländischer Ebene zusätzliche Gesetze und Vorschriften eingebracht haben oder derzeit erwägen.
„In the biopharmaceutical industry, AI is being increasingly used by companies and entities with which we compete. We are increasing our use of AI but other entities may be more advanced in their deployment and use of AI which may enhance such other entities’ business operations particularly their discovery efforts and the integration of operational efficiencies in the preclinical and clinical development of product candidates. If we are unable to use AI as effectively as our competitors, we could experience competitive disadvantages."
In der biopharmazeutischen Industrie wird KI zunehmend von Unternehmen und Einrichtungen eingesetzt, mit denen wir im Wettbewerb stehen. Wir weiten unseren KI-Einsatz aus, aber andere Akteure könnten bei der Einführung und Nutzung von KI weiter fortgeschritten sein, was deren Geschäftsbetrieb stärken könnte — insbesondere ihre Wirkstoffsuche und die Integration betrieblicher Effizienzgewinne in der präklinischen und klinischen Entwicklung von Produktkandidaten. Wenn wir KI nicht so wirksam einsetzen können wie unsere Wettbewerber, könnten wir Wettbewerbsnachteile erleiden.
„We are increasing our use of AI tools and technology throughout our business."
Wir weiten den Einsatz von KI-Werkzeugen und -Technologien in unserem gesamten Geschäftsbetrieb aus.
Filings Reviewed: 10-Q 2026-05-12 · 10-Q 2025-11-12 · 10-Q 2025-08-07 · 10-Q 2025-05-12 · 10-K 2026-03-05 · 10-K 2025-03-06
Rated on July 8, 2026 · How the Rating Is Built
Highlighted are things our editorial team noticed: green = stands out as strong, red = deserves a closer look. No single metric is a verdict on its own — always read it in context.
Quarterly Figures
| Quarter | EPS (Earnings Per Share) | EPS YoY (%) | Sales ($M) | Sales YoY (%) | Net Margin (%) | OCF ($M) | FCF ($M) |
|---|---|---|---|---|---|---|---|
| 2024: Q4 | -0.40 | – | 0 | – | -8,063.20 | -30 | -30 |
| 2025: Q1 | -0.40 | – | 0 | – | – | -31 | -31 |
| 2025: Q2 | -0.44 | – | 0 | – | – | -33 | -33 |
| 2025: Q3 | -0.53 | – | 0 | – | – | -40 | -40 |
| 2025: Q4 | -0.57 | – | 0 | -100.00 | – | -28 | -28 |
| 2026: Q1 | -0.57 | – | 0 | – | – | -46 | -46 |
- EPS (Earnings Per Share):
- Quarterly profit divided by the total share count — how much of the profit works out to a single share.
- YoY (Year over Year):
- Change versus the same quarter a year ago — this is how you compare without seasonal distortion (e.g. the holiday shopping season).
- Sales:
- All revenue for the quarter, before any costs are deducted — the top line of the income statement.
- Net Margin:
- What percentage of sales is left over as profit in the end. Negative means the company is posting a loss.
- OCF (Operating Cash Flow):
- The cash that actually flows into the till from the core business during the quarter — harder to dress up than book profit.
- FCF (Free Cash Flow):
- Operating cash flow minus capital expenditures — the money that's genuinely free to use, say for paying down debt, buybacks, or dividends.
About the Company
Atea Pharmaceuticals, Inc. , a clinical-stage biopharmaceutical company, discovers, develops, and commercializes oral antiviral therapeutics for patients with serious viral infections.
| Employees | 55 |
|---|---|
| Headquarters | Boston, MA |
| Website | ateapharma.com |
| IPO Date | 30. Oct 2020 |
| Next Earnings | 6. Aug 2026 |
Management
| Name | Title | Birth Year |
|---|---|---|
| Jean-Pierre Sommadossi Ph.D. | Founder, Chairman, CEO & President | 1956 |
| Andrea J. Corcoran J.D. | CFO, Executive VP of Legal & Secretary | 1962 |
| John F. Vavricka | Chief Commercial Officer | 1963 |
| Janet M. J. Hammond M.D., Ph.D. | Chief Development Officer | 1960 |
| Maria Arantxa Horga M.D. | Chief Medical Officer | 1968 |
| Wayne Foster CPA | Executive VP of Finance & Chief Accounting Officer | 1969 |
| Jonae R. Barnes | Senior Vice President of Investor Relations & Corporate Communications | – |
| Adel Moussa Ph.D. | Executive Vice President of Chemistry | – |
| Xiao-Jian Zhou Ph.D. | Executive Vice President of Early Stage Development | – |
| Keith Pietropaolo | Executive VP of Clinical Sciences & Project Management | – |
Executives per the latest required filings; titles kept in their original language. Source: fundamental data.
Chart
Interactive price chart (TradingView).
Data as of: July 20, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.